IL13RA2 and metastatic prostate carcinoma: Notably, the effects were seen with LNCaP cells, which normally express low levels of IL-13Rα2 and are sensitive only to high concentrations of Pep-1-Phor21, as well as with the metastatic prostate cancer cell lines DU145 and PC-3, which express higher IL-13Rα2 levels and are sensitive to Pep-1-Phor21, even in the absence of TSA or 5-aza-dC treatment.